DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tasurgratinib

Generic Name: Tasurgratinib

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

NCCH2006/MK010 Trial (FORTUNE Trial)

Phase 2

Active, not recruiting

Posted: 2021/07/15

Sponsor:

National Cancer Cent...

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Phase 1

Active, not recruiting

Posted: 2020/10/01

Sponsor:Eisai Co., Ltd.

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Phase 1

Completed

Posted: 2020/09/25

Sponsor:Eisai Co., Ltd.

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Phase 1

Recruiting

Posted: 2020/02/17

Sponsor:Eisai Co., Ltd.

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Phase 2

Active, not recruiting

Posted: 2020/01/23

Sponsor:Eisai Co., Ltd.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Eisai Partners with SciClone to Expand Tasurgratinib Access in Greater China for Biliary Tract Cancer Treatment

3 months ago

Eisai has licensed exclusive development and distribution rights for tasurgratinib, an FGFR-selective tyrosine kinase inhibitor, to SciClone Pharmaceuticals for the Greater China region.

Eisai Seeks Japanese Approval for Novel FGFR Inhibitor Tasurgratinib in Biliary Tract Cancer

3 months ago

Eisai has submitted tasurgratinib, a selective FGFR1/2/3 inhibitor, for priority review in Japan to treat biliary tract cancers with FGFR2 gene fusion mutations.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy